Introduction
============

Neuropathic pain (NeP) is defined as pain caused by a lesion or disease of the somatosensory nervous system. NeP is associated with conditions such as postherpetic neuralgia (PHN), diabetic peripheral neuropathy (DPN), and spinal cord injury (SCI).[@b1-jpr-12-1061],[@b2-jpr-12-1061] Chronic NeP can significantly reduce quality-of-life (QoL) and can impose a considerable economic burden on individual patients, their families, and society.[@b3-jpr-12-1061]

According to two surveys conducted in nationwide samples of the general Japanese population, the prevalence of NeP in Japan is estimated to be 3.2%.[@b4-jpr-12-1061],[@b5-jpr-12-1061] Although most research on the health and economic burdens of NeP conditions focuses on Western populations, available research in Japan indicates a considerable burden on the general population. Japanese patients with NeP have been shown to experience poorer QoL, higher psychological distress, greater sleep disturbance, and loss of work productivity compared with the general population.[@b4-jpr-12-1061],[@b6-jpr-12-1061]

A consistent finding among both Western and Asian populations is that most patients with NeP report the intensity of chronic pain as "moderate" or "severe" rather than as "mild".[@b7-jpr-12-1061]--[@b11-jpr-12-1061] Indeed, the burden of NeP is heavier in patients with more severe, chronic pain.[@b10-jpr-12-1061],[@b12-jpr-12-1061]--[@b14-jpr-12-1061] In addition, among patients diagnosed with a range of NeP conditions in routine clinical practice in the US, a significant association was found between pain severity and economic burden, with the highest costs incurred by patients with severe pain. Across NeP categories, high pain severity was associated with a heavier burden of comorbidities, increased use of healthcare resources and NeP medications, greater NeP-associated productivity loss, and considerable direct and indirect costs. In a multinational survey of subjects with DPN, reports from Asia, Latin America, and the Middle East concurred regarding difficulties in functioning, sleep, and general health status. Difficulties increased in tandem with pain severity, supporting the view that DPN, like other NeP conditions, is often inadequately managed and imposes a burden worldwide.[@b14-jpr-12-1061]

Pregabalin, an α2-δ ligand with analgesic properties, is an approved treatment option for NeP associated with PHN, DPN, and SCI in the US, and for the treatment of peripheral and central NeP in Europe and Japan.[@b15-jpr-12-1061],[@b16-jpr-12-1061] Pregabalin is also indicated for the management of fibromyalgia in the US and for the management of pain associated with fibromyalgia in Japan.[@b17-jpr-12-1061] The analgesic efficacy and safety of pregabalin in patients with NeP have been demonstrated in clinical trials conducted worldwide, including in the US, Europe, China, Japan, and Korea.[@b18-jpr-12-1061]--[@b30-jpr-12-1061] Pregabalin studies have also highlighted the importance of tailoring treatments to individual needs in order to improve the overall effectiveness of treatment regimens. Data pooled from 16 pregabalin trials in subjects with PHN or DPN suggest that the presence of comorbid sleep disturbance could predict pain relief in response to pregabalin.[@b31-jpr-12-1061] An analysis of pooled data from 11 pregabalin trials in DPN demonstrated that subjects with severe baseline pain experienced greater improvements in both pain relief and sleep disturbance than subjects with moderate pain.[@b32-jpr-12-1061]

Pooled analyses of global clinical trial data have shown that, in general, patients with moderate or severe baseline NeP respond well to pregabalin.[@b31-jpr-12-1061],[@b32-jpr-12-1061] However, because different regions and races can have distinct cultural and biological factors that may impact treatment responses, one should not assume that clinical evidence in one population would apply to another. To determine whether the previous international study findings are also evident in Japanese patients with NeP, the current study sought to demonstrate the therapeutic effects of pregabalin in subjects from Japan reporting moderate or severe baseline pain.

Materials and methods
=====================

Study design
------------

The three published randomized, double-blind, placebo-controlled, multicenter pregabalin trials are registered on [ClinicalTrials.gov](http://ClinicalTrials.gov) (sponsor study \#/[ClinicalTrials.gov](http://ClinicalTrials.gov) identifier: PHN study A0081120/NCT00394901,[@b30-jpr-12-1061],[@b33-jpr-12-1061] DPN study A0081163/NCT00553475,[@b22-jpr-12-1061],[@b30-jpr-12-1061] and SCI study A0081107/NCT00407745).[@b24-jpr-12-1061] The PHN (September 2006--November 2007) and DPN (October 2007--March 2009) trials were conducted in Japan, and the SCI trial (January 2007--February 2011) was conducted worldwide, but only data from the Japanese subpopulation were selected for the current analysis.

The PHN and DPN trials included a 1-week titration period, during which subjects received pregabalin 150 mg/day, titrated to 300 mg/day or 600 mg/day. The SCI trial included a 4-week dose optimization period, during which subjects received pregabalin 150 mg/day for 1 week, with titration up to 600 mg/day based on efficacy and tolerability. All trials included a placebo arm. The doses administered in all three trials were divided into two equal doses per day. Although treatment duration ranged from 13--16 weeks, excluding the taper periods ([Table 1](#t1-jpr-12-1061){ref-type="table"}), all trials included a fixed-dose/maintenance period of 12 weeks.

For all trials, subjects were selected for being aged ≥18 years and having a mean daily pain score ≥4 over a 7-day baseline period on an 11-point numeric rating scale (NRS, where 0=no pain and 10=worst possible pain). In the PHN and DPN studies, eligible subjects were required to score ≥40 mm on the 0--100 mm visual analog scale of the Short-Form McGill Pain Questionnaire at screening and randomization. The following primary diagnoses applied: 1) PHN (pain persisting ≥3 months after the healing of the herpes zoster rash); 2) DPN (history of type I or II diabetes mellitus for ≥1 year, with painful distal, symmetrical, sensorimotor polyneuropathy); and 3) SCI (complete or incomplete lesion ≥12-month duration at C2--T12 vertebrae).

The primary efficacy measure for the PHN and DPN studies was the endpoint mean pain score for the 7 days preceding study completion. In the SCI study, the primary endpoint was duration-adjusted average change based on pain scores recorded during the entire treatment period. Secondary efficacy endpoints included endpoint mean sleep interference score (sleep score) derived from the daily sleep diary (11-point NRS). The patient global impression of change questionnaire (PGIC) was also assessed at the end of the trial (where 1=very much improved and 7=very much worse). The incidence, severity, and relationship to study treatment of adverse events (AEs) were recorded for safety and tolerability assessments.

All trials included in the current analysis were approved by the appropriate institutional review boards or independent ethics committees at each investigational center. All trials were conducted in compliance with the ethical principles originating in or derived from the Declaration of Helsinki and in compliance with International Conference on Harmonization Good Clinical Practice guidelines. All participants provided written consent before entering a trial.

Statistical analysis
--------------------

Subjects who received at least one dose of study medication and who had a baseline pain score \>4 were included in the pooled efficacy and safety analysis. For all three trials, data from the pregabalin and placebo treatment groups were extracted into a single pregabalin-treatment and a single placebo-treatment group, respectively. Subjects were sub-grouped by baseline pain scores into severity categories of moderate (NRS pain score ≥4--\<7) or severe (≥7--10) pain. Demographics and baseline characteristics and the incidence of AEs were summarized by means of descriptive statistics.

Mean changes in pain and sleep interference scores at endpoint were analyzed using an analysis of variance model. For pain, the terms used were baseline pain severity, treatment, and protocol, and the interaction terms were treatment by baseline pain severity and treatment by protocol by baseline pain severity; protocol was used instead of indication. For sleep, similar interaction terms as in the pain severity analyses were used, but the terms also included baseline sleep score. Pain responders were defined as subjects with ≥30% or ≥50% reductions in mean pain score from the start of treatment to endpoint. PGIC responders were defined as subjects who were "much improved" or "very much improved". Pain and PGIC responder status were analyzed by a logistic regression model using terms for treatment and baseline pain severity, and terms for interaction between treatment and baseline severity. The percentage of subjects shifting from severe or moderate pain at baseline to mild, moderate, or severe pain at endpoint was calculated for each treatment arm. The last observation carried forward approach, commonly used in handling missing data for continuous measures, was used in efficacy analyses. The modified baseline carried forward approach, widely accepted to account for discontinuations due to treatment-related causes, was used for pain response endpoint analyses.

Results
=======

Demographics
------------

The study cohort consisted of 742 Japanese subjects with NeP. Most subjects reported moderate (n=513 \[69.1%\]) rather than severe baseline pain ([Table 2](#t2-jpr-12-1061){ref-type="table"}). The majority of subjects were male (65.2%), and median age ranged from 65--69 years. Within the moderate and severe pain cohorts, baseline mean pain scores were comparable between the pregabalin and placebo treatment groups ([Table 2](#t2-jpr-12-1061){ref-type="table"}). Higher sleep scores were reported in the severe pain cohort compared with the moderate pain cohort.

Efficacy
--------

Pregabalin treatment significantly reduced pain scores from baseline to endpoint compared with placebo in subjects with moderate (*P*\<0.001) or severe (*P*\<0.05) pain ([Table 3](#t3-jpr-12-1061){ref-type="table"}). A pronounced shift in pain burden was evident at therapeutic dose levels for PHN and DPN among patients with moderate or severe baseline pain ([Figure 1A and B](#f1-jpr-12-1061){ref-type="fig"}).

In the analysis of change from baseline to endpoint in mean sleep scores, significant improvement (*P*\<0.0001) was associated with pregabalin vs placebo treatment in subjects with moderate and severe baseline pain ([Table 3](#t3-jpr-12-1061){ref-type="table"}). A greater proportion of subjects with NeP achieved a ≥30% responder status for pain with pregabalin vs placebo in both pain severity cohorts (*P*\<0.05) ([Table 4](#t4-jpr-12-1061){ref-type="table"}). Although the proportion of subjects with NeP who achieved ≥50% pain responder status in both baseline pain severity cohorts was numerically greater in subjects treated with pregabalin than with placebo, the difference reached significance only in the severe pain cohort (*P*\<0.05). Pregabalin significantly improved the proportion of PGIC responders (score ≤2) at endpoint in both the moderate pain (*P*\<0.05) and severe pain (*P*\<0.01) cohorts ([Figure 2](#f2-jpr-12-1061){ref-type="fig"}).

Treatment with pregabalin successfully shifted 20%--30% of Japanese subjects with NeP across both levels of baseline pain severity to a category of lesser severity ([Figure 1](#f1-jpr-12-1061){ref-type="fig"}). In addition, greater proportions of subjects with severe pain at baseline shifted two pain levels (from severe to mild pain) at endpoint after treatment with pregabalin vs placebo.

Adverse events
--------------

Overall, 85%--87% of pregabalin-treated subjects in the moderate and severe baseline pain cohorts experienced at least one treatment-emergent AE (TEAE) compared with 66%--71% of placebo-treated subjects ([Table 5](#t5-jpr-12-1061){ref-type="table"}). Common AEs (reported in ≥10% of pregabalin-treated subjects and at twice the rate seen with placebo) observed in NeP subjects were consistent with the known safety profile of pregabalin and included dizziness, somnolence, weight gain, and peripheral edema.

Among pregabalin-treated subjects, 96 permanently withdrew from the studies because of TEAEs, of which 69 events were judged to be treatment-related by the investigators. Treatment-related AEs were cited in 4.7%, 12.4%, and 18.9% of study discontinuations from the groups given pregabalin 150, 300, and 600 mg/day, respectively, and in 9.4% of those who received pregabalin flexible dosing. The highest rate of discontinuation from study was observed at the maximum pregabalin dose level. Treatment-related TEAEs were cited in 3.9% of permanent discontinuations by placebo-treated subjects. Only one subject, in the pregabalin 150 mg/day group, permanently discontinued study because of a laboratory abnormality. Lack of efficacy was the reason given for 4.7%, 1.5%, and 0.9% of permanent discontinuations from the pregabalin 150, 300, and 600 mg/day groups, but not in the flexible-dose group. Overall, 15.1%, 20.1%, 24.5%, and 15.6% of subjects in the pregabalin 150, 300, 600 mg/day, and flexible-dose groups discontinued pregabalin, whereas 13.5% of subjects discontinued placebo.

Discussion
==========

In this current pooled analysis in Japanese subjects with NeP, pregabalin was efficacious in improving pain relief, sleep quality, and PGIC scores, regardless of baseline pain severity. Pregabalin was well tolerated in this patient population.

The therapeutic efficacy of pregabalin for reducing mean pain and sleep scores at endpoint appeared to be comparable between subjects with severe and moderate baseline pain ([Table 3](#t3-jpr-12-1061){ref-type="table"}). Although there were numerical differences in the odds of achieving 30% pain responder status at endpoint between subjects with baseline severe pain compared with moderate pain, the overlapping 95% CIs suggested that the odds were not meaningfully different, regardless of pain severity. This is in contrast to conclusions from previous international pooled studies, in which subjects with severe baseline pain experienced greater therapeutic benefits with pregabalin than did subjects with moderate baseline pain.[@b32-jpr-12-1061] Consistent with that study, however, subjects in the current study with severe baseline NeP had significantly higher odds (vs placebo) to be 50% pain responders at endpoint, but subjects with moderate baseline pain only demonstrated numerically (but not statistically significantly) higher odds than placebo. Additional research would be warranted to explore the aforementioned differences between the previous global study and this study conducted in Japan (eg, what impact do cultural and biological differences have on these outcomes?).

Subjects with severe pain at baseline "shifted" to mild pain at nearly twice the frequency after treatment with pregabalin (21.33%) compared with placebo (11.39%). Overall, 20%--30% of Japanese subjects with NeP who had moderate-to-severe pain at baseline had improved to experiencing mild-to-moderate pain after 13--16 weeks of pregabalin treatment.

Overall improvement in global health status appeared to be comparable regardless of baseline pain severity, as observed by the proportion of PGIC responders at endpoint being comparable between subjects with moderate and severe baseline pain. The incidence of commonly experienced AEs (dizziness, somnolence, weight gain, and peripheral edema) with pregabalin was generally low, and consistent with its known safety profile.[@b15-jpr-12-1061]--[@b17-jpr-12-1061]

Limitations
===========

A few limitations of the current analysis need to be considered. First, fewer subjects were drawn from the SCI study than from the PHN and DPN studies. In addition, pain and sleep efficacy assessments relied on patient diary entries, which, despite being a standard procedure in the evaluation of analgesic efficacy, could possibly introduce self-reporting bias. Finally, this is a post hoc pooled analysis of clinical trial data and, as such, these analyses were not prespecified in the original study designs of the source trials.

Conclusion
==========

In this analysis, pregabalin (compared with placebo) was efficacious in reducing mean pain score and improving sleep in Japanese subjects with either moderate or severe NeP at baseline. In addition, both pain severity groups had significant odds of achieving 30% pain responder status, and the severe baseline pain group of becoming 50% pain responders. Both baseline pain severity groups shifted to lower categories of pain (eg, severe to moderate, severe to mild, moderate to mild) at a frequency higher than placebo. Although numerical differences in the above parameters were observed between subjects with severe vs moderate baseline pain, the overlapping error values suggested these differences were not meaningful. Finally, pregabalin was generally well tolerated in these subjects. These findings appear to support the premise that pregabalin is an efficacious treatment for improving pain and sleep, irrespective of pain severity in subjects in Japan.
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![Pain shift from baseline to endpoint for mean pain score by (**A**) moderate (≥4--\<7) and (**B**) severe (≥7--≤10) baseline pain criteria in pregabalin and placebo treatment groups.\
**Notes:** Population: subjects in pregabalin studies NCT00394901 (PHN), NCT00553475 (DPN), and modified intent-to-treat Japanese subjects in pregabalin study NCT00407745 (SCI). Percentages are based on n for each treatment; n, total number of subjects with baseline mean pain ≥4--≤10.\
**Abbreviations:** DPN, diabetic peripheral neuropathy; PHN, post-herpetic neuralgia; SCI, spinal cord injury.](jpr-12-1061Fig1){#f1-jpr-12-1061}

![PGIC responders at endpoint by baseline pain severity.\
**Notes:** \**P*\<0.05. PGIC responders were subjects who scored "much improved" (score=2) or "very much improved" (score=1) on a scale of 1--7. Baseline pain scores were defined as moderate (≥4--\<7) or severe (≥7--10). Logistic regression model used with terms for treatment and baseline pain severity (moderate or severe) and interaction term of baseline severity and treatment as the categorical covariates.\
**Abbreviation:** PGIC, patient global impression of change.](jpr-12-1061Fig2){#f2-jpr-12-1061}

###### 

Summary of neuropathic pain studies included in the analysis

  Condition (study number/[ClinicalTrials.gov](http://ClinicalTrials.gov) identifier)   Total treatment phase/maintenance phase (weeks)   Pregabalin maintenance dose (mg/day)                       Administration      No. of participants[a](#tfn1-jpr-12-1061){ref-type="table-fn"}         
  ------------------------------------------------------------------------------------- ------------------------------------------------- ---------------------------------------------------------- ------------------- ---------------------------------------------------------------- ----- -----
  PHN (A0081120/NCT00394901)[@b30-jpr-12-1061],[@b34-jpr-12-1061]                       13/12                                             150, 300, 600[b](#tfn2-jpr-12-1061){ref-type="table-fn"}   BID fixed dose      97                                                               272   369
  DPN (A0081163/NCT00553475)[@b22-jpr-12-1061],[@b30-jpr-12-1061]                       13/12                                             300, 600[b](#tfn2-jpr-12-1061){ref-type="table-fn"}        BID fixed dose      135                                                              179   314
  SCI (A0081107/NCT00407745)[@b24-jpr-12-1061]                                          16/12                                             150--600                                                   BID flexible dose   27                                                               32    59

**Notes:**

Efficacy analyses were performed on all randomized subjects with baseline mean pain score ≥4 who had received at least one dose of study medication, with at least one post-baseline entry in the daily pain diary for each trial. Efficacy analysis for the SCI trial was based on the Japanese subpopulation.

All trials included a matching placebo treatment arm.

**Abbreviations:** BID, twice-daily; DPN, diabetic peripheral neuropathy; PHN, post-herpetic neuralgia; SCI, spinal cord injury.

###### 

Baseline demographic and clinical characteristics

                                                                      NeP population[a](#tfn5-jpr-12-1061){ref-type="table-fn"}: baseline pain[b](#tfn6-jpr-12-1061){ref-type="table-fn"}                               
  ------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------- ------------- ------------- -------------
  N                                                                   333                                                                                                                   180           150           79
  Age, years, median (range)                                          66 (24--92)                                                                                                           65 (28--88)   69 (27--88)   68 (27--87)
  Sex, n (%)                                                                                                                                                                                                            
   Female                                                             118 (35.4)                                                                                                            52 (28.9)     66 (44.0)     22 (27.9)
   Male                                                               215 (64.6)                                                                                                            128 (71.1)    84 (56.0)     57 (72.2)
  Duration of NeP-related pain, months, mean (SD)                     44.2 (50.4)                                                                                                           47.2 (45.9)   53.3 (65.9)   49.7 (49.3)
  Pain score,[b](#tfn6-jpr-12-1061){ref-type="table-fn"} mean (SD)    5.4 (0.8)                                                                                                             5.4 (0.8)     8.0 (0.9)     7.9 (0.8)
  Sleep score,[c](#tfn7-jpr-12-1061){ref-type="table-fn"} mean (SD)   3.2 (2.1)                                                                                                             3.5 (2.0)     5.3 (2.8)     5.4 (2.8)

**Notes:** Subjects with baseline pain \<4 and missing baseline pain scores are excluded.

Includes pregabalin 150, 300, 600 mg/day, and flexible 150--600 mg/day treatment groups.

Pain scores range from 0=no pain to 10=worst possible pain; scores of ≥4--\<7 were classified as moderate and ≥7--≤10 were classified as severe.

Sleep scores range from 0=pain does not interfere with sleep to 10=pain completely interferes with sleep.

**Abbreviation:** NeP, neuropathic pain.

###### 

Change in mean pain and sleep scores from baseline to endpoint (LOCF analysis)

                                                                          Pregabalin   Placebo        Difference from placebo                                 
  ----------------------------------------------------------------------- ------------ -------------- ------------------------- -------------- -------------- ---------
  **Change in pain score**[a](#tfn10-jpr-12-1061){ref-type="table-fn"}                                                                                        
  NeP[b](#tfn11-jpr-12-1061){ref-type="table-fn"}                                                                                                             
   Moderate                                                               333          −1.74 (0.17)   180                       −0.74 (0.19)   −1.00 (0.26)   \<0.001
   Severe                                                                 150          −1.77 (0.20)   79                        −1.05 (0.23)   −0.72 (0.31)   0.018
  **Change in sleep score**[c](#tfn12-jpr-12-1061){ref-type="table-fn"}                                                                                       
  NeP[b](#tfn11-jpr-12-1061){ref-type="table-fn"}                                                                                                             
   Moderate                                                               333          −1.47 (0.15)   180                       −0.44 (0.17)   −1.03 (0.22)   \<0.001
   Severe                                                                 150          −1.32 (0.18)   79                        −0.19 (0.20)   −1.13 (0.27)   \<0.001

**Notes:** ANOVA model includes baseline pain severity, treatment, and indication (study). Sleep model also included baseline sleep score. Second interaction term included treatment, indication, and baseline pain severity. Subjects with baseline pain \<4 and missing baseline pain scores are excluded.

Pain scores range from 0=no pain to 10=worst possible pain; scores of ≥4--\<7 were classified as moderate and ≥7--≤10 were classified as severe.

Includes pregabalin 150, 300, 600 mg/day, and flexible 150--600 mg/day treatment groups.

Sleep scores range from 0=pain does not interfere with sleep to 10=pain completely interferes with sleep.

**Abbreviations:** LOCF, last observation carried forward; LS, least squares; NeP, neuropathic pain.

###### 

Analysis of 30% and 50% pain responders at mBOCF endpoint in NeP

                                                                                                     vs placebo                
  ----------------------------------------------------------------- ---------------- --------------- ------------ ------------ -------
  30% pain responders[a](#tfn15-jpr-12-1061){ref-type="table-fn"}                                                              
   Moderate[b](#tfn16-jpr-12-1061){ref-type="table-fn"}             154/333 (46.3)   63/180 (35.0)   1.60         1.10--2.32   0.014
   Severe[b](#tfn16-jpr-12-1061){ref-type="table-fn"}               48/150 (32.0)    15/79 (19.0)    2.01         1.04--3.88   0.038
  50% pain responders[a](#tfn15-jpr-12-1061){ref-type="table-fn"}                                                              
   Moderate[b](#tfn16-jpr-12-1061){ref-type="table-fn"}             95/333 (28.5)    38/180 (21.1)   1.49         0.97--2.29   0.068
   Severe[b](#tfn16-jpr-12-1061){ref-type="table-fn"}               32/150 (21.3)    7/79 (8.9)      2.79         1.17--6.65   0.021

**Notes:** Subjects with baseline pain \<4 and missing baseline pain scores are excluded. NeP population includes pregabalin 150, 300, 600 mg/day, and flexible 150--600 mg/day treatment groups. Logistic regression model used with terms for treatment and baseline pain severity (either moderate or severe) and interaction terms of treatment and baseline severity as the categorical covariates.

Pain responders were subjects with ≥30% or ≥50% reduction in mean pain score from baseline to endpoint.

Baseline pain scores were defined as moderate (≥4--\<7) or severe (≥7--10).

**Abbreviation:** mBOCF, modified baseline carried forward approach; NeP, neuropathic pain; OR, odds ratio.

###### 

Summary of treatment-emergent AEs (all-causality) by baseline pain severity in neuropathic pain

                                                           Baseline pain[a](#tfn19-jpr-12-1061){ref-type="table-fn"}                             
  -------------------------------------------------------- ----------------------------------------------------------- ------------ ------------ -----------
  Subjects with ≥1 AE                                      282 (84.7)                                                  127 (70.6)   131 (87.3)   52 (65.8)
  Common AEs[c](#tfn21-jpr-12-1061){ref-type="table-fn"}                                                                                         
   Dizziness                                               99 (29.7)                                                   11 (6.1)     39 (26.0)    6 (7.6)
   Somnolence                                              98 (29.4)                                                   20 (11.1)    43 (28.7)    2 (2.5)
   Weight gain                                             44 (13.2)                                                   3 (1.7)      15 (10.0)    3 (3.8)
   Constipation                                            32 (9.6)                                                    6 (3.3)      13 (8.7)     3 (3.8)
   Peripheral edema                                        44 (13.2)                                                   6 (3.3)      15 (10.0)    2 (2.5)

**Notes:** Subjects with baseline pain \<4 and missing baseline pain scores are excluded.

Baseline pain scores defined as moderate (≥4--\<7) or severe (≥7--10).

Defined by Medical Dictionary of Regulatory Activities preferred terms.

Reported in ≥5% of subjects and at twice the rate of placebo within a disease cohort.

**Abbreviation:** AE, adverse event.
